Chronix Biomedical is pioneering a breakthrough approach to the diagnosis and management of cancer. It has developed proprietary blood tests that measure unique cancer DNA sequences. The Company is focused on blood tests for breast and prostate cancer. Chronix is headquartered in San Jose, California and has a research facility in Germany. HDL recently raised Series E and Series F financing (both rounds totalled $4.8M ) for the Company to continue its commercialization. (click to see Press Release)
UPDATE: since these financings, Chronix went on to sign a major licensing deal with Myriad Genetics Inc. (NASDAQ: "MYGN"). (click to see Press Release).
|
>> Visit the Site >> Back to Menu
|
